Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:depression
|
| gptkbp:approves |
gptkb:2015
gptkb:FDA |
| gptkbp:bioavailability |
approximately 60%
|
| gptkbp:brand |
gptkb:Vraylar
|
| gptkbp:casnumber |
864812-26-0
|
| gptkbp:chemical_formula |
C20 H28 N2 O
|
| gptkbp:clinical_trial |
Phase III
Cariprazine in the Treatment of Bipolar Disorder Efficacy and Safety of Cariprazine in Patients with Schizophrenia |
| gptkbp:contraindication |
hypersensitivity to the drug
severe hepatic impairment |
| gptkbp:developed_by |
Gedeon Richter
|
| gptkbp:duration |
short-term
long-term |
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
gptkb:tablet
gptkb:capsule |
| https://www.w3.org/2000/01/rdf-schema#label |
Cariprazine
|
| gptkbp:indication |
maintenance treatment of bipolar disorder
treatment of depressive episodes in bipolar disorder acute manic or mixed episodes of bipolar I disorder |
| gptkbp:ingredients |
Cariprazine hydrochloride
|
| gptkbp:interacts_with |
CYP3 A4 inducers
CYP3 A4 inhibitors |
| gptkbp:lifespan |
approximately 2-5 days
|
| gptkbp:marketed_as |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:mechanism_of_action |
dopamine D3 and D2 receptor partial agonist
|
| gptkbp:metabolism |
gptkb:CYP3_A4
|
| gptkbp:patient_population |
adults
adolescents |
| gptkbp:pharmacokinetics |
antipsychotic effects
mood stabilizing effects |
| gptkbp:research_focus |
bipolar disorder treatment
schizophrenia treatment |
| gptkbp:route_of_administration |
oral
|
| gptkbp:side_effect |
anxiety
dizziness fatigue nausea insomnia constipation dry mouth weight gain sedation hyperlipidemia hyperglycemia extrapyramidal symptoms akathisia tardive dyskinesia orthostatic hypotension |
| gptkbp:used_for |
treatment of schizophrenia
treatment of bipolar disorder |
| gptkbp:bfsParent |
gptkb:Sunovion_Pharmaceuticals
gptkb:The_Upjohn_Company |
| gptkbp:bfsLayer |
7
|